Tadalafil + Placebo + Alpha1 Blocker

ApprovedCompleted
0 watching 0 views this week๐Ÿ”ฅ Hot
85
Hype Score

Development Stage

โœ“
Pre-clinical
โœ“
Phase 1
โœ“
Phase 2
โœ“
Phase 3
5
Approved
Indication / Disease

Benign Prostatic Hyperplasia

Conditions

Benign Prostatic Hyperplasia

Trial Timeline

Apr 1, 2015 โ†’ Feb 1, 2016

About Tadalafil + Placebo + Alpha1 Blocker

Tadalafil + Placebo + Alpha1 Blocker is a approved stage product being developed by Eli Lilly for Benign Prostatic Hyperplasia. The current trial status is completed. This product is registered under clinical trial identifier NCT02431754. Target conditions include Benign Prostatic Hyperplasia.

Hype Score Breakdown

Clinical
30
Activity
20
Company
10
Novelty
10
Community
12

Clinical Trials (1)

NCT IDPhaseStatus
NCT02431754ApprovedCompleted

Competing Products

20 competing products in Benign Prostatic Hyperplasia

See all competitors